411 related articles for article (PubMed ID: 27031538)
1. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
[TBL] [Abstract][Full Text] [Related]
2. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
3. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
4. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
5. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
7. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
Dika E; Ravaioli GM; Fanti PA; Piraccini BM; Lambertini M; Chessa MA; Baraldi C; Ribero S; Andrea A; Melotti B; Patrizi A
Eur J Dermatol; 2017 Jun; 27(3):266-270. PubMed ID: 28524050
[TBL] [Abstract][Full Text] [Related]
8. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Adler NR; Murray WK; Brady B; McCormack C; Pan Y
Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
[No Abstract] [Full Text] [Related]
9. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
Abdallah AO; Herlopian A; Ravilla R; Bansal M; Chandra-Reddy S; Mahmoud F; Ong S; Gokden M; Hutchins L
J Oncol Pharm Pract; 2016 Jun; 22(3):537-42. PubMed ID: 25712627
[TBL] [Abstract][Full Text] [Related]
10. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
11. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
12. Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam.
Qu YJ; Jin SB; Han XC; Zheng LQ
An Bras Dermatol; 2016; 91(6):808-810. PubMed ID: 28099605
[TBL] [Abstract][Full Text] [Related]
13. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
15. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
[No Abstract] [Full Text] [Related]
16. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
[No Abstract] [Full Text] [Related]
17. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
18. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
Cervantes J; Rosen A; Dehesa L; Dickinson G; Alonso-Llamazares J
Actas Dermosifiliogr (Engl Ed); 2019; 110(1):43-49. PubMed ID: 30389125
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
20. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma.
Sakaguchi C; Yano S; Ashida K; Wada N; Ohe K; Nagata H; Matsuda Y; Sakamoto S; Sakamoto R; Ohnaka K; Uchi H; Furue M; Nomura M; Ogawa Y
Am J Case Rep; 2019 Jan; 20():106-110. PubMed ID: 30679413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]